Guardant health stock - How To Discuss
Guardant health stock
What is Guardant Health's (GHC) stock price potential upside? His predictions range from $ to $. On average, they expect Guardant Healths' stock price to hit $100 over the next 12 months. This indicates a possible rise in the current share price.
What are analysts'price targets for Guardant Health's stock?
11 Equity Research analysts have released annual target prices for Guardant Health stock. Your prediction is between $ and $. On average, they expect Guardant Health's stock price to hit $100 in the next 12 months.
Who owns guardguardant health stock?
Guardant Health shares are held by a number of retail and institutional investors. The main institutional investors are Morgan Stanley , BlackRock Inc. , Capital Research Global Investors , Viking Global Investors LP , Coatue Management LLC and Credit Suisse AG .
Are Guardant Health's earnings expected to grow in the next year?
Guardant Health's earnings are expected to rise from ($) to ($) per share next year. Guardant Health's P/E ratio is , which means earnings are negative and cannot be compared to companies with positive earnings.
What is the 12-month stock price forecast for Guardant Health?
The stock price forecast for 12 months is , an increase from the last price. CITY OF REDWOOD, (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, today announced that the company will attend its upcoming 40th annual meeting.
Is GH stock a buy or sell?
14 analysts rate GH stock as average buy. The stock price forecast for 12 months is , an increase from the last price.
How did Guardant Health's sales beat Wall Street's Q3 estimates?
Guardant Health Inc (NASDAQ:GH) had third-quarter revenue of $3 million, up 27% year over year, better than Wall Street's estimate of $3 million. Guards Precision Oncology revenue increased 31% to $79 in the third quarter.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Why do hedge funds keep piling into Guardant Health?
Hedge funds continue to pile on Guardant Health, Inc. (GH) Investing in small cap stocks has always been a way to outperform the market, as small caps tend to grow faster than blue chip companies. This superiority comes at a price, however, as there are sometimes periods of heightened volatility.
What does Guardant Health do for a living?
Analyst Report: Guardian Health, Inc. Headquartered in Redwood City, California, Guardant Health offers blood and cancer testing for clinical and research use, and the company has research partnerships with major biopharmaceutical companies.
![:brown_circle:]( ":brown_circle:")
Is guardant’s target market trending?
Guardant is cautiously targeting oncology submarkets that are likely to face less competition, such as: B. Residual disease and treatment options. Market valuations for Guardant may be conservative if liquid biopsy rollout progresses faster than expected.
What is guardant’s pipeline?
The company's portfolio includes Guardant Reveal (formerly Lunar1) to detect cancer recurrence in survivors and Lunar2, a liquid biopsy for early detection of cancer in high-risk individuals, with an initial focus on colorectal cancer. In addition, Guardant offers research development services.
What is the price of the Guardant Health share price?
Today at 04:42 UTC, Guardant Health shares are trading at $. This heading information is delayed by 15 minutes. How has Guardant Health's share price changed this year?
What is the price targets for GH stock?
The high target price for GH is $ and the low target price for GH is $. There are currently 6 buy prices for a stock that result in a corresponding buy price.
What is guardguardant health?
Guardian Health Inc. is a precision oncology company. The company focuses on fighting cancer through blood tests, datasets and advanced analytics. The company has developed Guardant360, Guardant360 CDx and GuardantOMNI-based liquid biopsy tests for the diagnosis of advanced cancers.
![:brown_circle:]( ":brown_circle:")
What is the difference between guardant360 CDX and guardantomni tests?
The Guardant360 CDx test is a fluid-based biopsy that measures 55 genes associated with cancer. Their GuardantOMNI test has a larger panel of 500 genes, each of which looks at deoxyribonucleic acid (DNA) from a tumor circulating in the blood.
What are analysts' price targets for guardant health' s stock 2018
Based on ratings provided by 9 analysts last year, the consensus rating for Guardant Health stock is Buy, based on a current rating of 1 Hold and 8 Buy ratings for GH. Guardant Health's 12-month average price target is $ with a high $ target and a low $ target.
Who owns guard guardant health stock predictions
These are anti-cartel belts. Guardian Health Inc. is a precision oncology company dedicated to treating cancer with its own blood tests, big data sets and advanced analytics. Decisions include choice of treatment, detection of recurrence, and early detection.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What does guardguardant health do?
Guardian Health Inc. is a precision oncology company dedicated to treating cancer with its own blood tests, big data sets and advanced analytics. Decisions include choice of treatment, detection of recurrence, and early detection.
What are analysts' price targets for guardant health' s stock 2020
Guardant Health's 12-month average price target is $ with a high $ target and a low $ target. Learn more Do Wall Street analysts think Guardant Health outperforms its competitors? Analysts like Guardant Health own more shares than other healthcare companies.
What is it like to work at Guardant Health?
Cancer affects millions of people, but at Guardant Health you pay attention to each person and encourage yourself to see each patient as part of your family. You will work with scientists, engineers, doctors, business people, reimbursement specialists and many others.
How do I contact guardguardant health?
Guardian Health Inc. 505 Penobscot Dr. Redwood City, CA 94063 Phone: .
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Does guardant offer research development services?
In addition, Guardant offers research development services. The United States accounts for 90% of total sales, while other markets account for the remaining 10%.
Who owns guard guardant health stock news
Motley Fool owns shares in and supports Guardant Health and NeoGenomics, Inc. Motley Fool has a disclosure policy.
![:brown_circle:]( ":brown_circle:")
Is Guardant Health's opportunity for colorectal cancer reveal Big?
The Guardant Health features for Guardant Reveal should be great. Colon cancer returns at an early stage in 10% to 30% of patients. Currently, there are more than a million people in the country who have had colon cancer.
When is Guardant Health's next earnings release?
When is the next Guardian Health sale date? Guardant Health plans to release its next quarterly report on Wednesday, February 23, 2022. View Guardian Health's revenue forecast.
How much does Guardant Health make a year?
Guardant Health has a market cap in the billions of dollars and annual sales in the millions of dollars. The company earns millions of dollars each year in net income (earnings) or ($) based on earnings per share. How many employees does Guardian Health have? Guardant Health employs 864 people worldwide.
How did guardguardant Health's (GH) Q4 earnings compare to analysts'estimates?
Guardian Health Inc. (NASDAQ:GH) released its quarterly earnings on Thursday, Nov. The company reported ($) earnings per share (EPS) for the quarter, below the analyst consensus estimate of ($)$. The company made millions of dollars in the quarter, compared to analysts' expectations of millions of dollars.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
How much of Guardant Health's stock are insiders buying and selling?
Guardant Health's experts have bought more shares of your company in the past three months than they have sold. Specifically, they bought the company's stock for $10,048 and sold the company's stock for $1,035. Insiders only own shares in Guardian Health.
Is Guardant Health's P/E ratio overvalued?
Guardant Health's P/E ratio is , which means earnings are negative and cannot be compared to companies with positive earnings. Guardant Health has a P/E ratio A P/E ratio of more than 3 indicates that the company may be overvalued in relation to its assets and liabilities. Should I buy Guardian Health now?
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
Are guardant health' s earnings expected to grow in the next year 2020
It is clear that Guardant Health's revenue growth is expected to slow significantly, with revenue expected to grow at 39% in the coming year, compared to a historic growth rate of 61% in the last year of the past year.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
Are guardant health' s earnings expected to grow in the next year 2019
After a surprise of 25 cents a share, Wall Street analysts raised their 2019 consensus forecast by 39 cents to a loss of 88 cents from a loss of $. They also increased their forecast from dollar loss to dollar loss for the coming years. Guardant's revenue is expected to grow 30% to $1 million.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
Are guardant health' s earnings expected to grow in the next year today
Guardant Health's earnings are expected to rise from ($) to ($) per share next year. Guardant Health has not officially confirmed when its next earnings release will be released, but the company's estimated earnings date is Wednesday, February 23, 2022, based on previous years' reporting data.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is the upside for Guardant Health's stock?
Your prediction is between $ and $. On average, they expect Guardant Health's stock price to hit $100 in the next 12 months. This indicates a possible rise in the current share price. View price targets from analysts at Guardant Health or top stocks from Wall Street analysts.
Who owns Guardant Health stock?
Company members who own shares in Guardant Health include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A. Bertocci, Helmi Eltukhi, Ian T. Clark, Michael J. Wylie, Samir Kaul, Stanley J. Meresman and Stanley J. Meresmann. View Guardian Health Institutional Ownership Trends. Who are the main investors selling Guardant Health shares?
